Sign inCreate account

Report workspace tools

NCT00130247COMPLETEDanonymous

A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment

Sponsor

Source record

National Institute of Allergy and Infectious Diseases (NIAID)

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.

Indication / condition

AI-normalized

Tuberculosis

Intervention

Source record

Ethambutol, Isoniazid, Pyrazinamide, Rifampin

Source & freshness

Source record

NCT ID

NCT00130247

Original source

ClinicalTrials.gov

Source last updated

Nov 08, 2018

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00130247

Title

A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Status

COMPLETED

Phase

Phase 3

Condition raw

Tuberculosis

Condition normalized

Tuberculosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.

Target normalized

Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.

Interventions

Ethambutol, Isoniazid, Pyrazinamide, Rifampin

Public preview

Source record

This clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), investigates the efficacy of a shortened 4-month anti-TB treatment regimen compared to the standard 6-month regimen in HIV-non-infected patients with drug-susceptible pulmonary tuberculosis. The trial's completion and results could significantly impact treatment guidelines, potentially leading to increased patient adherence and reduced healthcare costs. The market for tuberculosis treatment remains substantial, especially in endemic regions, and successful outcomes may enhance the competitive positioning of existing therapies. Companies involved in TB treatment may need to evaluate their portfolios in light of these findings, particularly regarding the potential for shorter treatment regimens to gain market share.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00130247

Status

COMPLETED

Phase

Phase 3

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), investigates the efficacy of a shortened 4-month anti-TB treatment regimen compared to the standard 6-month regimen in HIV-non-infected patients with drug-susceptible pulmonary tuberculosis. The trial's completion and results could significantly impact treatment guidelines, potentially leading to increased patient adherence and reduced healthcare costs. The market for tuberculosis treatment remains substantial, especially in endemic regions, and successful outcomes may enhance the competitive positioning of existing therapies. Companies involved in TB treatment may need to evaluate their portfolios in light of these findings, particularly regarding the potential for shorter treatment regimens to gain market share.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 08, 2018
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00130247

Indication

Tuberculosis

Modality

small molecule

Target

Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.

Intervention

Ethambutol, Isoniazid, Pyrazinamide, Rifampin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.